Mednikov Roman V, Rabinovich Vladislav I, Kizlo Svetlana N, Belyakov Nikolai A, Sokolov Alexey A
Saint-Petersburg Center for Control of AIDS and Infectious Diseases, Saint-Petersburg, Russia.
North-Western State Medical University, Saint-Petersburg, Russia.
Ther Apher Dial. 2016 Aug;20(4):413-9. doi: 10.1111/1744-9987.12396. Epub 2016 Apr 5.
One of the main causes of mortality of human immunodeficiency virus (HIV)-infected patients are complications of chronic hepatitis C virus (HCV). Combining drug therapy for HCV with double filtration plasmapheresis (DFPP) has significantly increased the effectiveness of treatment for these patients. However, there are no data on the use of this method for the treatment of patients co-infected with HIV and HCV. We demonstrated that positive clinical effect in the treatment of HCV patients by DFPP (previously demonstrated) is also achieved in the treatment of HIV infected patients, co-infected with HCV. The obtained efficiency of 62.5% is almost two times higher than the predicted treatment efficiency. We can conclude that the complex therapy of hepatitis C, including DFPP and medication by PEG-IFN + RBV is an effective and safe approach for the treatment of HCV in patients co-infected with HCV and HIV.
人类免疫缺陷病毒(HIV)感染患者死亡的主要原因之一是慢性丙型肝炎病毒(HCV)的并发症。将HCV药物治疗与双重过滤血浆置换术(DFPP)相结合,显著提高了这些患者的治疗效果。然而,关于该方法用于治疗HIV和HCV合并感染患者的数据尚不存在。我们证明,DFPP治疗HCV患者(先前已证明)所取得的积极临床效果在治疗合并HCV感染的HIV感染患者中也能实现。所获得的62.5%的有效率几乎比预测的治疗有效率高出两倍。我们可以得出结论,丙型肝炎的综合治疗,包括DFPP和聚乙二醇干扰素+利巴韦林药物治疗,是治疗HCV和HIV合并感染患者HCV的一种有效且安全的方法。